ABVX:EPA
Abivax SA
76,10 €
arrow_downward
-0,72%(-0,55) 1D
19 қар., 17:35:26 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
77,35 €
High
79,30 €
Low
75,85 €
Mkt. cap
6,75 млрд
Avg. vol.
110,41 м.
Volume
150,52 м.
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
77,35 €
High
79,30 €
Low
75,85 €
Mkt. cap
6,75 млрд
Avg. vol.
110,41 м.
Volume
150,52 м.
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
The Harvard Law School Forum on Corporate Governance
·
8 сағат бұрын
Board Practices and Composition in the Russell 3000 and S&P 500
The Motley Fool
·
11 сағат бұрын
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
Barron's
·
8 сағат бұрын
S&P 500 Futures Rise in Premarket Trading; Credicorp, Intercorp Finl Svcs Lead
24/7 Wall St.
·
9 сағат бұрын
4 S&P 500 Dividend Stocks Paying Shareholders More Than Their Free Cash Flow
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013 ж. 04 жел.
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com